NCT02926690: Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

NCT02926690
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known central nervous system (CNS) or leptomeningeal metastases that require therapy will not be eligible for the dose expansion cohort, but are eligible for the dose escalation cohort
https://ClinicalTrials.gov/show/NCT02926690

Comments are closed.

Up ↑